Print View Attached Docs:
Alias Names: ABL Mutation Screening / BCR-ABL Sequencing / Imatinib (Gleevec) Resistance / TK Receptor
Methodology: Sequencing
Edit Date: 4/13/2009
Performed: Once weekly
Released: 7-10 days after setup at PeaceHealth Laboratories’ reference lab.
CPT Code: 83891-902B / 83894-902B / 83898-902B x2 / 83909-902B x2 / 83912-902B / 86902-902B
Specimen Collection Details
Collection: Six to seven 4 mL lavender top tube (EDTA) peripheral blood. Draw Monday-Thursday only. Also acceptable: Bone marrow. Note that the lower volume of bone marrow specimen reduces the number of cells and therefore the probability of detecting very low-level leukemia burdens in patients with minimal residual disease. media.
Handling: BLOOD: Stabilize peripheral blood by mixing with RPMI media in equal volumes of blood to media (1:1 ratio). Keep refrigerated. Indicate on the requisition the volume of RPMI tissue culture media used. Specimen MUST be received at PeaceHealth Laboratories’ reference lab within 24 hours of collection.
BONE MARROW: Draw in a heparinized syringe and transfer to an EDTA collection tube. Mix with an equal volume (1:1 ratio) of RPMI. Keep refrigerated.
Stability: Unstable frozen.
Standard Volume: 30 mL whole blood.
Minimum Volume: 20 mL whole blood.
Transport: Refrigerated.
Comments: Direct sequencing of the ABL kinase domain.
Rejection Criteria: Clotted, frozen, or leaking specimen.
This test may require insurance company prior authorization before ordering.
Please check the prior authorization list
Failure to gain preauthorization may result in denial of coverage.

Family Medicine for America's Health